Formerra to Supply Foster Medical Compounds Across the Americas
ROMEOVILLE, IL / ACCESS Newswire / July 15, 2025 / Formerra, a leader in performance materials distribution, today announced an agreement with GEON® Performance Solutions that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in North America and South America.
The agreement follows GEON's acquisition of Foster, LLC, and builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials.
"This expanded partnership equips our customers with a broader set of proven medical-grade solutions while leveraging Formerra's technical guidance and robust supply-chain capabilities," said Kelly Wessner, Vice President, Key Accounts, Formerra. "Foster's brand strength and GEON's investment momentum create powerful growth potential for these materials and our customers."
Foster, LLC brings more than 30 years of expertise in custom medical polymer compounding, offering highly engineered formulations. Ranging from radio-opaque and pre-colored to USP Class VI and ISO 10993-compliant grades, Foster materials serve critical applications such as medical device housings, drug-delivery and auto-injector components, surgical tools, and remote patient monitoring devices.
"It is a privilege to serve the high-growth healthcare and medical device industry as GEON embarks on this new journey with Foster and Formerra," said Arthur Adams, Chief Commercial Officer, GEON. "Our partnership with Formerra will expand our global footprint and enable us to distribute medical-grade engineered polymers to even more customers."
With the addition of Foster, LLC compounds to its portfolio, Formerra further deepens its leading position in the healthcare space by delivering unmatched access to engineered medical polymers, deep regulatory expertise, and responsive logistics across the Americas.
Key details
--Formerra will distribute Foster®, LLC medical compounds in North and South America.--This agreement adds custom medical-grade compounds to Formerra's existing global access to GEON® PVC and filled PP materials.--Foster®, LLC material applications include medical device housings, drug-delivery and auto-injectors, surgical tools, remote patient monitoring components, and more.
About Formerra
Formerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.
About GEON
GEON® Performance Solutions is a global leader in the formulation, development and manufacture of performance polymer solutions. With a portfolio of highly adaptable vinyl and polyolefin polymer technologies as well as a full-service manufacturing business, GEON combines three powerful traditions into a single, customer-focused business. GEON Performance Solutions is a leading innovator in the development of performance material solutions for a broad range of markets including appliances, building & infrastructure, electronics, medical, transportation, power & communications and more. GEON Performance Solutions has approximately 1,200 global associates and 15 world-class manufacturing plants with headquarters in Westlake, Ohio. Please visit us at www.geon.com to learn more. GEON Performance Solutions is a portfolio company of SK Capital Partners.
Media Contact
Jackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com
SOURCE: Formerra
press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
30 minutes ago
- Business Wire
SWBC Mortgage Honored with 2025 Home Possible RISE Awards® for Fastest Growth by Freddie Mac
SAN ANTONIO--(BUSINESS WIRE)--SWBC Mortgage Corporation is proud to announce that it has been named a 2025 Home Possible RISE Awards® winner by Freddie Mac in the prestigious 'Fastest Growth' category for Regional Independent Mortgage Bankers. We remain committed to helping families across the country achieve the dream of homeownership through innovative, accessible, and sustainable lending solutions. The annual program, Recognizing Individuals for Sustained Excellence (RISE) Awards, celebrates top sellers across multiple categories for excellence with Freddie Mac Home Possible® and Housing Finance Agency (HFA) Advantage® mortgages—affordable lending solutions expanding access to low- to moderate-income borrowers. This recognition, awarded in May 2025, underscores SWBC Mortgage's strong dedication to expanding homeownership opportunities and addressing affordability challenges through innovative and responsible lending solutions. The company earned this distinction based on its significant loan volume growth between the first and second half of 2024. 'We are honored to receive this award from Freddie Mac. This recognition is a testament to the hard work and dedication of our entire team,' said Kerry Dannenberg, President of SWBC Mortgage. 'We remain committed to helping families across the country achieve the dream of homeownership through innovative, accessible, and sustainable lending solutions.' For more information about SWBC Mortgage and its lending programs, visit our website. About SWBC Mortgage Corporation SWBC Mortgage Corporation, a wholly owned subsidiary of SWBC, is a full-service mortgage lender approved by FNMA, FHLMC, and GNMA. Headquartered in San Antonio, Texas, SWBC Mortgage has been providing mortgage banking services since 1988. Through the changing landscape of the mortgage industry, the company has remained committed to service, integrity, and stability while growing to serve communities and borrowers in 44 states + D.C. Today, SWBC Mortgage is consistently recognized as one of the top 50 lenders in America and is home to numerous top-ranked originators. Building on a rich history of success, SWBC Mortgage has highly experienced team members who leverage streamlined digital tools to deliver efficient service and support, while providing a personal, experienced touch to the mortgage process. SWBC Mortgage provides innovative technology and resources built to streamline the mortgage process and provide support from application through servicing. About SWBC As a diversified financial services company, SWBC provides financial institutions, businesses, and individuals with a wide range of insurance, mortgages, wealth management, employee benefits, and more. Headquartered in San Antonio, Texas, SWBC has partners and divisions across all 50 states and Mexico and manages businesses worldwide. No matter how wide its reach, SWBC always listens to our customers' needs, analyzes their current situations, and recommends customized solutions. For more information about our innovative approach to personalized service, visit SWBC's website.
Yahoo
an hour ago
- Yahoo
Bora Pharmaceuticals Announces Multi-Year Expansion for Midwest Manufacturing Site, as Upsher-Smith Entity Split is Finalized
Buildout includes Gerteis Macro-Pactor® install, with additional investments to follow, to meet industry demand at Minnesota facility MAPLE GROVE, Minn., August 05, 2025--(BUSINESS WIRE)--Bora Pharmaceuticals Co., Ltd. ("Bora" or "the Company", TWSE: 6472), a global leader in pharmaceutical manufacturing, has announced plans for significant investments to expand its manufacturing and packaging capabilities at its facility in Maple Grove, Minnesota. This is a major upgrade to the site, which Bora acquired in 2024 as part of its $210 million acquisition of Upsher-Smith Laboratories, expanding its U.S. manufacturing footprint. As the entity separation from Upsher-Smith Laboratories takes effect on August 5, Bora continues its growth amid surging demand for oral solid dose (OSD) development and manufacturing brought on by increasingly complex formulations, novel drug delivery technologies, and the growing shift of biologics into OSD formats. Bora has already secured multiple multi-million-dollar contracts for development and commercial supply of advanced OSD programs. "With pharmaceutical companies relying more heavily on specialized CDMO partners to scale production and maintain quality, top-tier manufacturing capacity and technical expertise are at a premium," said J.D. Mowery, president of Bora's CDMO business. "Bora's Maple Grove facility offers a unique opportunity for innovators to secure space in a state-of-the-art site staffed by experts in formulation development, tech transfer, and commercial manufacturing." The first phase of Bora's investment will add a Gerteis Macro-Pactor® at the company's state-of-the-art site. This investment initiates a broader buildout of 100,000 square feet of dedicated shell space designed to streamline production for partners with high-volume needs. The Gerteis Macro-Pactor® roller compactor will be installed and operational in the third quarter of 2025. "As we complete our transition from Upsher-Smith, we're creating the infrastructure to deliver integrated manufacturing, packaging, and analytical services with the speed and quality our clients need," shared Dennis Hall, Vice President and General Manager of the Maple Grove site. "As we expand our capabilities, we look forward to tapping into all the experience and talent in the area." The facility offers on-site quality control laboratories and a dedicated development team to support product and analytical development as well as innovation. It is an FDA-inspected manufacturing site and meets global health authority requirements, ensuring regulatory compliance. From early development and scale-up to process optimization and commercial manufacturing, Bora's experienced teams support customers at every stage of the product lifecycle. The company's commercial on-time, in-full (OTIF) delivery record is unmatched, reinforcing Bora's role as a trusted partner, supporting clients with secure, consistent supply. For more information, visit About Bora Pharmaceuticals Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products. From our world-class sites in North America and Asia, we deliver drug products with unparalleled quality to more than 100 markets around the world. For more information, visit View source version on Contacts Liz Robinsonlrobinson@ 847-702-8099
Business Wire
an hour ago
- Business Wire
Bora Pharmaceuticals Announces Multi-Year Expansion for Midwest Manufacturing Site, as Upsher-Smith Entity Split is Finalized
MAPLE GROVE, Minn.--(BUSINESS WIRE)-- Bora Pharmaceuticals Co., Ltd. ('Bora' or 'the Company', TWSE: 6472), a global leader in pharmaceutical manufacturing, has announced plans for significant investments to expand its manufacturing and packaging capabilities at its facility in Maple Grove, Minnesota. This is a major upgrade to the site, which Bora acquired in 2024 as part of its $210 million acquisition of Upsher-Smith Laboratories, expanding its U.S. manufacturing footprint. 'Bora's Maple Grove facility offers a unique opportunity for large pharmaceutical innovators to secure space in a state-of-the-art site staffed by experts in formulation development, tech transfer, and commercial manufacturing,' said J.D. Mowery. As the entity separation from Upsher-Smith Laboratories takes effect on August 5, Bora continues its growth amid surging demand for oral solid dose (OSD) development and manufacturing brought on by increasingly complex formulations, novel drug delivery technologies, and the growing shift of biologics into OSD formats. Bora has already secured multiple multi-million-dollar contracts for development and commercial supply of advanced OSD programs. 'With pharmaceutical companies relying more heavily on specialized CDMO partners to scale production and maintain quality, top-tier manufacturing capacity and technical expertise are at a premium,' said J.D. Mowery, president of Bora's CDMO business. 'Bora's Maple Grove facility offers a unique opportunity for innovators to secure space in a state-of-the-art site staffed by experts in formulation development, tech transfer, and commercial manufacturing.' The first phase of Bora's investment will add a Gerteis Macro-Pactor® at the company's state-of-the-art site. This investment initiates a broader buildout of 100,000 square feet of dedicated shell space designed to streamline production for partners with high-volume needs. The Gerteis Macro-Pactor® roller compactor will be installed and operational in the third quarter of 2025. 'As we complete our transition from Upsher-Smith, we're creating the infrastructure to deliver integrated manufacturing, packaging, and analytical services with the speed and quality our clients need,' shared Dennis Hall, Vice President and General Manager of the Maple Grove site. 'As we expand our capabilities, we look forward to tapping into all the experience and talent in the area.' The facility offers on-site quality control laboratories and a dedicated development team to support product and analytical development as well as innovation. It is an FDA-inspected manufacturing site and meets global health authority requirements, ensuring regulatory compliance. From early development and scale-up to process optimization and commercial manufacturing, Bora's experienced teams support customers at every stage of the product lifecycle. The company's commercial on-time, in-full (OTIF) delivery record is unmatched, reinforcing Bora's role as a trusted partner, supporting clients with secure, consistent supply. For more information, visit About Bora Pharmaceuticals Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products. From our world-class sites in North America and Asia, we deliver drug products with unparalleled quality to more than 100 markets around the world. For more information, visit
